Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit
Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. Learn how you can help make a difference by joining the All of Us Research Program.
Displaying 41 - 50 of 267
Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)
Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)
Protocol No
GI-YARUR-SPARC
Categories
Assessment of Cardiovascular Risk in Inflammatory Bowel Disease Patients
Cardiovascular Risk in IBD
Protocol No
GI-IIT-SINH-CV-IN-IBD
Categories
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)
Protocol No
ECOG-EA8212-BRIDGE
Categories
Effects of Transcranial Direct Current Stimulation (tDCS) on Language
Effects of Transcranial Direct Current Stimulation (tDCS) on Language
Protocol No
NEURO-AHW-TDCS-LANGUAGE
Categories
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Ma
Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
Protocol No
ADP-0000-001-SCR
Categories
Cancer,
Gynecologic Cancers,
Prostate and Urologic Cancers,
Other Respiratory,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Ovary,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Head and Neck Cancers,
Gastrointestinal Cancers,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus,
Colorectal
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Compl
Rituximab with or without SCT in Treating Pt with MRD-Neg MCL in First Complete Remission
Protocol No
ECOG-EA4151
Categories
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory MM
Protocol No
IIT-DHAKAL-IMPEDE-SGZ-12356
Categories
Combination Post-transplant Consolidation Therapy with Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients with Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)
The purpose of this study is to test the safety and effectiveness of the new study drug combination of Isatuximab, Lenalidomide, and Dexamethasone for the treatment of multiple myeloma in patients with Persistent Marrow Minimal Residual Disease.
Protocol No
IIT-MOHAN-E-MAT
Categories
A Randomized, Open-Label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in Comparison with Atezolizumab Plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A randomized study to compare Atezolizumab plus Chemotherapy vs HLX10 plus Chemo in ES-SCLC
Protocol No
SHB-HLX10-005-SCLC301-E
Categories
A Phase II Trial of De-escalated PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
A Phase 2 Trial of PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Allogenic HCT
Protocol No
IIT-ABEDIN-PTCY-RUX-GVHD
Categories